Literature DB >> 10551709

Myocardial cell death in fibrillating and dilated human right atria.

C Aimé-Sempé1, T Folliguet, C Rücker-Martin, M Krajewska, S Krajewska, M Heimburger, M Aubier, J J Mercadier, J C Reed, S N Hatem.   

Abstract

OBJECTIVES: The aim of the present study was to determine if myocytes can die by apoptosis in fibrillating and dilated human atria.
BACKGROUND: The cellular remodeling that occurs during atrial fibrillation (AF) may reflect a degree of dedifferentiation of the atrial myocardium, a process that may be reversible.
METHODS: We examined human right atrial myocardium specimens (n = 50) for the presence of apoptotic myocytes. We used immunohistochemical and Western blotting analysis to examine the expression of a final effector of programmed cell death, caspase-3 (CASP-3) and of regulatory proteins from the BCL-2 family.
RESULTS: Sections from atria in AF contained a high percentage of large myocytes with a disrupted sarcomeric apparatus replaced by glycogen granules (64.4 +/- 6.3% vs. 12.2 +/- 5.8%). These abnormal myocytes, which also predominated in atria from hearts with decreased left ventricular ejection fraction (42.3 +/- 10.1%), contained large nuclei, most of which were TUNEL positive, indicating a degree of DNA breakage. None of these abnormal myocytes expressed the proliferative antigen Ki-67. A small percentage of the enlarged nuclei (4.2 +/- 0.8%) contained condensed chromatin and were strongly TUNEL positive. Both the pro- and activated forms of CASP-3 were detected in diseased myocardial samples, which also showed stronger CASP-3 expression than controls. Expression of the antiapoptotic BCL-2 protein was decreased in diseased atria, whereas that of the proapoptotic BAX protein remained unchanged.
CONCLUSIONS: In fibrillating and dilated atria, apoptotic death of myocytes with myolysis contributes to cellular remodeling, which may not be entirely reversible.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551709     DOI: 10.1016/s0735-1097(99)00382-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  56 in total

1.  Right atrial myocardial deformation by two-dimensional speckle tracking echocardiography predicts recurrence in paroxysmal atrial fibrillation.

Authors:  Malini Govindan; Anatoli Kiotsekoglou; Samir K Saha; A John Camm
Journal:  J Echocardiogr       Date:  2017-06-21

2.  Angiotensin II in atrial structural remodeling: the role of Ang II/JAK/STAT3 signaling pathway.

Authors:  Liuying Zheng; Xiaogang Jia; Cheng Zhang; Dong Wang; Zhongnan Cao; Jin Wang; Xinping Du
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

3.  Compartmentation of energy metabolism in atrial myocardium of patients undergoing cardiac surgery.

Authors:  Evelin Seppet; Margus Eimre; Nadezhda Peet; Kalju Paju; Ehte Orlova; Mati Ress; Sirje Kõvask; Andres Piirsoo; Valdur A Saks; Frank N Gellerich; Stephan Zierz; Enn K Seppet
Journal:  Mol Cell Biochem       Date:  2005-02       Impact factor: 3.396

4.  C-reactive protein levels and atrial fibrillation after cardiac surgery in women.

Authors:  Charles W Hogue; Christopher A Palin; Rajagopal Kailasam; Jennifer S Lawton; Abdullah Nassief; Victor G Dávila-Román; Betsy Thomas; Ralph Damiano
Journal:  Ann Thorac Surg       Date:  2006-07       Impact factor: 4.330

5.  Window current through the T-type Ca2+ channel triggers the mechanism for cellular apoptosis via mitochondrial pathways.

Authors:  Tomoko Uchino; Shojiro Isomoto; Takayuki Noguchi; Katsushige Ono
Journal:  Heart Vessels       Date:  2013-01-18       Impact factor: 2.037

6.  Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing.

Authors:  J Zhao; J Li; W Li; Y Li; H Shan; Y Gong; B Yang
Journal:  Br J Pharmacol       Date:  2010-01-15       Impact factor: 8.739

7.  Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid.

Authors:  J Jehle; I Staudacher; F Wiedmann; Pa Schweizer; R Becker; Ha Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

8.  Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study.

Authors:  Hiroshi Watanabe; Naohito Tanabe; Toru Watanabe; Dawood Darbar; Dan M Roden; Shigeru Sasaki; Yoshifusa Aizawa
Journal:  Circulation       Date:  2008-02-19       Impact factor: 29.690

9.  Recent advances in pharmacotherapy of atrial fibrillation.

Authors:  J Singh; J S Braich
Journal:  Indian J Pharmacol       Date:  2009-08       Impact factor: 1.200

10.  Bepridil Suppresses Apoptosis in HL-1 Cardiac Atrial Myocytes Expressing Mutant E334K cMyBPC.

Authors:  Ryo Endo; Tomomi Notsu; Mutsuo Mishima; Kumi Morikawa; Peili Li; Nobuhito Ikeda; Haruaki Ninomiya; Yasuaki Shirayoshi; Ichiro Hisatome
Journal:  Yonago Acta Med       Date:  2013-11-28       Impact factor: 1.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.